natgillin/translations-raw huggingface dataset:
• Tenofovir alafenamide is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
• alafenamidtenofovirat je „predzdravilo“ tenofovirja, kar pomeni, da se v učinkovino tenofovir pretvori v telesu.
• Emtricitabine is also a reverse transcriptase inhibitor and it works in the same way as tenofovir.
• emtricitabin je zaviralec reverzne transkriptaze in deluje enako kot tenofovir.
Symtuza can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection.
Predpisovanje in izdaja zdravila Symtuza je le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem okužb z virusom HIV.
• Cobicistat acts as a ‘booster' to increase the effects of darunavir, by slowing down the breakdown of darunavir and therefore prolonging its antiviral activity in the body.
• kobicistat deluje kot „ojačevalec“ in okrepi učinke darunavirja, tako da upočasni njegovo hitrost razgradnje in s tem podaljša čas njegovega delovanja v telesu;
Symtuza was also as effective as a similar combination medicine containing tenofovir disoproxil in place of tenofovir alafenamide.
Zdravilo Symtuza je bilo tudi tako učinkovito kot podobno kombinirano zdravilo, ki namesto alafenamidtenofovirata vsebuje dizoproksiltenofovirat.
Tenofovir is a reverse transcriptase inhibitor, which means that it blocks the activity of the enzyme, reverse transcriptase, that the virus needs to reproduce itself.
Tenofovir je zaviralec reverzne transkriptaze, kar pomeni, da zavira delovanje reverzne transkriptaze, drugega encima, ki virusu omogoča razmnoževanje;
How is Symtuza used?
Kako se zdravilo Symtuza uporablja?
How does Symtuza work?
Kako zdravilo Symtuza deluje?
Symtuza contains the active substances darunavir, cobicistat, emtricitabine and tenofovir alafenamide.
Zdravilo Symtuza vsebuje učinkovine darunavir, kobicistat, emtricitabin in alafenamidtenofovirat.
For the full list of side effects reported with Symtuza, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Symtuza, glejte navodilo za uporabo.
This overview was last updated in 08-2018.
Povzetek je bil nazadnje posodobljen 08-2018.
However, given the extreme rarity of the condition, the safety database is small and rare events are not expected to be captured during the clinical studies.
Vendar je glede na izjemno redkost bolezni zbirka podatkov o varnosti majhna in tako ni možno pričakovati, da bi se med kliničnimi študijami zabeležili redki neželeni učinki.
Further information on Coagadex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije za zdravilo Coagadex so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Medicines Agency decided that the benefits of Coagadex are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Coagadex večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Coagadex?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Coagadex?
Coagadex received a marketing authorisation valid throughout the EU on 16 March 2016.
Za zdravilo Coagadex je bilo 16. marca 2016 izdano dovoljenje za promet, veljavno po vsej EU.
The main measure of effectiveness was based on the doctor's and patient's assessment of how well the treatment worked in preventing and treating bleeding episodes.
Glavno merilo učinkovitosti je temeljilo na zdravnikovi in bolnikovi oceni, kako učinkovito je bilo zdravljenje pri preprečevanju in zdravljenju epizod krvavitev.
Coagadex has been investigated in one main study involving 16 patients with hereditary factor X deficiency aged 12 to 58 years.
Zdravilo Coagadex je bilo raziskano v eni glavni študiji, ki je vključevala 16 bolnikov s pomanjkanjem faktorja X, starih od 12 do 58 let.
For the treatment of bleeding, 187 bleeding episodes were recorded and assessed, and treatment with Coagadex was rated as ‘excellent' or ‘good' for 98.4% of bleeding episodes.
Pri zdravljenju krvavitev je bilo zabeleženih in ocenjenih 187 epizod krvavitev, pri čemer je bilo zdravljenje z zdravilom Coagadex ocenjeno kot „odlično“ ali „dobro“ v 98,4 % epizod krvavitev.
In a study with 9 children aged less than 12 years (4 of whom were under4 years of age), a routine preventive treatment with Coagadex over 6 months was rated as excellent in reducing or preventing bleeding episodes.
V študiji pri devetih otrocih, mlajših od 12 let (od katerih so bili štirje mlajši od štirih let) je bilo šestmesečno rutinsko profilaktično zdravljenje z zdravilom Coagadex ocenjeno kot odlično za zmanjševanje ali preprečevanje epizod krvavitev.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Coagadex have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Coagadex upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The most common side effects with Coagadex (which may affect up to 1 in 10 people) are pain or redness at the injection site, fatigue (tiredness), and back pain.
Najpogostejši neželeni učinki zdravila Coagadex (ki se lahko pojavijo pri največ 1 od 10 bolnikov) so bolečina ali pordelost na mestu injiciranja, utrujenost in bolečina v hrbtu.
As for all medicines, data on the use of Coagadex are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Coagadex stalno spremljajo.
Coagadex (human coagulation factor X)
Coagadex (humani koagulacijski faktor X)
The Agency considered the lack of specific therapies for factor X deficiency, and concluded that Coagadex was effective at treating and preventing bleeding in patients with the condition.
Agencija je upoštevala pomanjkanje specifičnih zdravljenj pomanjkanja faktorja X in zaključila, da je bilo zdravilo Coagadex učinkovito pri zdravljenju in preprečevanju krvavitev pri bolnikih s tem stanjem.
For more information about using Coagadex, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Coagadex glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The dose and frequency of the injections depend on the severity of the patient's factor X deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Odmerek in pogostnost injiciranja sta odvisna od resnosti bolnikovega pomanjkanja faktorja X, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
In these patients, blood clots do not form properly, resulting in bleeding that does not stop easily and poor wound healing.
Pri teh bolnikih se krvni strdek ne oblikuje pravilno, zaradi česar se krvavitev ne ustavi zlahka in se rana slabo celi.
These reactions have not been reported during clinical studies with Coagadex.
O teh reakcijah med kliničnimi študijami z zdravilom Coagadex niso poročali.
Factor X deficiency is rare and Coagadex was designated an ‘orphan medicine' (a medicine used in rare diseases) on 14 September 2007.
Pomanjkanje faktorja X je redko, zato je bilo zdravilo Coagadex 14. septembra 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Coagadex is given by injection into a vein.
Zdravilo Coagadex se daje z injekcijo v veno.
Why is Coagadex authorised in the EU?
Zakaj je bilo zdravilo Coagadex odobreno v EU?
An overview of Coagadex and why it is authorised in the EU
Pregled zdravila Coagadex in zakaj je odobreno v EU
Other information about Coagadex
Druge informacije o zdravilu Coagadex
In total, 10 bleeds were reported in the study, of which 4 were treated with Coagadex.
Skupaj so v študiji poročali o desetih krvavitvah, od katerih so z zdravilom Coagadex zdravili štiri.
Side effects reported with Coagadex are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Coagadex, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
Hypersensitivity (allergic) reactions can occur rarely in patients treated for bleeding disorders (in up to 1 patient in 1,000) and can be severe in some cases.
Pri bolnikih, zdravljenih zaradi motenj krvavitve (pri do 1 od 1 000 bolnikov) se redko lahko pojavijo preobčutljivostne (alergijske) reakcije, ki so lahko v nekaterih primerih hude.
The side effects of Coagadex were considered manageable and of mild or moderate intensity.
Neželeni učinki zdravila Coagadex so bili ocenjeni kot obvladljivi ter blage ali zmerne jakosti.
What benefits of Coagadex have been shown in studies?
Kakšne koristi zdravila Coagadex so se pokazale v študijah?
Patients received Coagadex either to treat any spontaneous bleeding during the treatment period or to prevent bleeding during surgery.
Bolniki v študiji so prejeli zdravilo Coagadex za zdravljenje kakršne koli spontane krvavitve v obdobju zdravljenja ali za preprečevanje krvavitve med kirurškim posegom.
For 3 minor surgeries during the study, Coagadex was rated as excellent in preventing bleeding episodes.
Pri treh manjših kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Coagadex ocenjeno kot odlično za preprečevanje epizod krvavitev.
Patients may inject Coagadex themselves at home once they have been trained appropriately.
Bolniki si lahko po primernem usposabljanju zdravilo Coagadex injicirajo sami doma.
What is Coagadex and what is it used for?
Kaj je zdravilo Coagadex in za kaj se uporablja?
What are the risks associated with Coagadex?
Kakšna tveganja so povezana z zdravilom Coagadex?
A single infusion of Coagadex was sufficient to control each treated bleeding event.
Ena infuzija zdravila Coagadex je zadostovala za nadzor posamezne zdravljene krvavitve.
Patients with hereditary factor X deficiency lack factor X, a protein needed to form the blood clot that stops wounds from bleeding.
Bolniki z dednim pomanjkanjem faktorja X nimajo dovolj faktorja X, beljakovine, ki je potrebna za nastanek krvnega strdka, ki zaustavi krvavenje iz rane.
The active substance in Coagadex is human factor X isolated from the plasma of blood donors.
Učinkovina zdravila Coagadex je humani faktor X, pridobljen iz plazme darovalcev krvi.
For the full list of side effects and restrictions with Coagadex, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Coagadex glejte navodilo za uporabo.
Coagadex can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in the treatment of rare bleeding disorders.
Predpisovanje in izdaja zdravila Coagadex je le na recept, zdravljenje z njim pa se sme uvesti in izvajati samo pod nadzorom zdravnika z izkušnjami z zdravljenjem redkih motenj strjevanja krvi.
Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation Coagadex contains the active substance human coagulation factor X.
Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
By replacing the missing factor X, Coagadex helps the blood to clot and gives temporary control of bleeding.
Nadomešča manjkajoči faktor X ter tako pripomore k strjevanju krvi in omogoči začasen nadzor nad krvavitvijo.
How does Coagadex work?
Kako zdravilo Coagadex deluje?
How is Coagadex used?
Kako se zdravilo Coagadex uporablja?
Coagadex is a medicine used for the treatment and prevention of bleeding (including during and after an operation) in patients with hereditary factor X deficiency.
Coagadex je zdravilo, ki se uporablja za zdravljenje in preprečevanje krvavitev (tudi med kirurškimi posegi in po njih) pri bolnikih z dednim pomanjkanjem faktorja X. Pomanjkanje faktorja X je motnja strjevanja krvi, ki jo povzroči pomanjkanje faktorja X, beljakovine, ki je potrebna za normalno strjevanje krvi.
This summary was last updated in 06-2008.
Povzetek je bil nazadnje posodobljen 06-2008.
The study continued for over three years.
Študija je trajala več kot tri leta.
It is available as light green oval tablets (30, 60 or 90 mg).
Na voljo je v obliki svetlozelenih ovalnih tablet (30, 60 ali 90 mg).
The studies lasted for six months.
Študije so trajale šest mesecev.
The European Commission granted a marketing authorisation valid throughout the European Union for Parareg on 22 October 2004.
Evropska komisija je dovoljenje za promet z zdravilom Parareg, veljavno po vsej Evropski uniji, odobrila dne 22. oktobra 2004.
The marketing authorisation holder is Dompé Biotec S.p.A.
Imetnik dovoljenja za promet je družba Dompé Biotec S.p.A.
Other information about Parareg:
Druge informacije o zdravilu Parareg:
It can be used as part of treatment including phosphate binders or vitamin D sterols.
Uporablja se lahko kot del zdravljenja, ki vključuje vezalce fosfatov ali sterole vitamina D.
Parareg is used in adults and elderly patients:
Zdravilo Parareg se uporablja pri odraslih in starostnikih:
This means that it mimics the action of calcium in the body.
To pomeni, da posnema učinkovanje kalcija v telesu.
It can lead to bone and joint pain and deformities of the arms and legs.
Posledica so lahko bolečine v kosteh in sklepih ter deformacije rok in nog.
This is a condition in which the parathyroid glands in the neck produce too much parathyroid hormone (PTH).
To je stanje, pri katerem obščitnice v vratu tvorijo preveč paratiroidnega hormona (PTH).
‘Primary' means that the hyperparathyroidism is not caused by any
„Primarni“ pomeni, da hiperparatiroidizem ni posledica nobenega drugega
The Committee recommended that Parareg be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Parareg odobri dovoljenje za promet.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PARAREG EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) PARAREG Povzetek EPAR za javnost
Parareg is taken with food or shortly after a meal.
Zdravilo Parareg se jemlje s hrano ali takoj po zaužitju obroka.
• to treat secondary hyperparathyroidism.
• za zdravljenje sekundarnega hiperparatiroidizma.
What benefit has Parareg shown during the studies?
Kakšne koristi je zdravilo Parareg izkazalo med študijami?
The dose of Parareg should be increased every two to four weeks up to 90 mg three or four times a day as necessary to reduce blood calcium to normal levels.
Odmerek zdravila Parareg je treba povečevati vsakih dva do štiri tedne do vrednosti 90 mg tri- ali štirikrat dnevno, kolikor je potrebno za znižanje ravni kalcija v krvi na normalno raven.
Of these, 45 went on to a fourth, long-term study looking at the effectiveness of Parareg over a total of almost six years.
nadaljevalo v četrti, dolgoročni študiji, ki je preučevala učinkovitost zdravila Parareg v trajanju skoraj šest let.
Parareg should not be used in people who may be hypersensitive (allergic) to cinacalcet or any of the other ingredients.
Zdravila Parareg ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) cinakalcet ali katero koli drugo sestavino zdravila.
What is the risk associated with Parareg?
Kakšna tveganja so povezana z zdravilom Parareg?
Parareg produced a decrease in blood calcium of more than 1 mg/dl in 62% of the cancer patients (18 out of 29) and in 88% of the patients with primary hyperparathyroidism(15 out of 17).
Zdravilo Parareg je privedlo do znižanja ravni kalcija v krvi za več kot 1 mg/dl pri 62 % bolnikov z rakom (pri 18 bolnikih od 29) in pri 88 % bolnikov s primarnim hiperparatiroidizmom (pri 15 bolnikih od 17).
The reduction in PTH levels also leads to a decrease in blood calcium levels.
Zmanjšanje ravni paratiroidnega hormona privede do znižanja ravni kalcija v krvi.
In secondary hyperparathyroidism, the recommended starting dose for adults is 30 mg once a day.
Pri sekundarnem hiperparatiroidizmu je priporočeni začetni odmerek za odrasle 30 mg enkrat dnevno.
Blood calcium levels should be measured frequently, and within one week of each dose adjustment of Parareg.
Ravni kalcija v krvi je treba meriti pogosto in v enem tednu po vsaki prilagoditvi odmerka zdravila Parareg.
Parareg is a medicine containing the active substance cinacalcet.
Parareg je zdravilo, ki vsebuje zdravilno učinkovino cinakalcet.
The results of the additional studies supported the use of Parareg for hypercalcaemia in patients with primary hyperparathyroidism.
Rezultati dodatnih študij so podprli uporabo zdravila Parareg pri zdravljenju hiperkalciemije pri bolnikih s primarnim hiperparatiroidizmom.
For the full list of all side effects reported with Parareg, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Parareg, glejte navodilo za uporabo.
Parareg is used in patients with serious kidney disease who need dialysis to clear their blood of waste products.
Zdravilo Parareg se uporablja pri bolnikih s hudim obolenjem ledvic, ki za očiščenje odpadnih snovi iz krvi potrebujejo dializo.
Parareg has been studied in three main studies involving 1,136 dialysis patients with serious kidney disease.
Zdravilo Parareg so preučevali v treh glavnih študijah, ki so vključevale 1136 dializnih bolnikov s hudim obolenjem ledvic.
Why has Parareg been approved?
Zakaj je bilo zdravilo Parareg odobreno?
Once a maintenance dose has been established, calcium levels should be measured monthly and PTH levels should be measured every one to three months.
Ko je vzdrževalni odmerek določen, je treba ravni kalcija meriti enkrat na mesec, ravni paratiroidnega hormona pa vsakih en do tri mesece.
The dose is adjusted every two to four weeks, according the patient's PTH levels, up to a maximum of 180 mg once a day.
Odmerek se prilagodi vsake dva do štiri tedne v skladu z bolnikovimi ravnmi paratiroidnega hormona do maksimalno 180 mg enkrat dnevno.
Parareg brought about a 42% reduction in PTH levels compared with an increase of 8% in patients taking placebo.
Zdravilo Parareg je zmanjšalo ravni paratiroidnega hormona za 42 % v primerjavi s povečanjem za 8 % pri bolnikih, ki so jemali placebo.
‘Secondary' means that the hyperparathyroidism is caused by another condition.
„Sekundarni“ pomeni, da hiperparatiroidizem nastane kot posledica drugega bolezenskega stanja.
The main measure of effectiveness was the number of patients who had a reduction in blood calcium levels of more than 1 mg per decilitre by the time a maintenance dose had been found (between two and 16 weeks after the start of the study).
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so se ravni kalcija v krvi zmanjšale za več kot 1 mg na deciliter do trenutka, ko so zdravniki uspeli ugotoviti vzdrževalni odmerek (med drugim im 16. tednom po začetku študije).
In patients with parathyroid carcinoma or primary hyperparathyroidism, the recommended starting dose of Parareg for adults is 30 mg twice a day.
Pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom je priporočeni začetni odmerek zdravila Parareg za odrasle 30 mg dvakrat dnevno.
The main measure of effectiveness was the number of patients who had a PTH level below 250 micrograms per litre at the end of the study.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so imeli ob koncu študije raven paratiroidnega hormona pod 250 mikrogramov na liter.
The active substance in Parareg, cinacalcet, is a calcimimetic agent.
Zdravilna učinkovina v zdravilu Parareg, cinakalcet, je kalcimimetično sredstvo.
• to reduce hypercalcaemia (high blood calcium levels) in patients with parathyroid carcinoma (cancer of the parathyroid glands), or in patients with primary hyperparathyroidism who cannot have their parathyroid glands removed or when the doctor thinks that removal of the parathyroid glands is not appropriate.
• za zmanjšanje hiperkalciemije (visokih ravni kalcija v krvi) pri bolnikih s paratiroidnim karcinomom (rakom obščitnic) ali pri bolnikih s primarnim hiperparatiroidizmom, pri katerih odstranitev obščitnic ni možna, ali za katere zdravnik meni, da odstranitev obščitnic zanje ni primerna.
Parareg has also been studied in a study involving 46 patients with hypercalcaemia, including 29 with parathyroid carcinoma and 17 with primary hyperparathyroidism who could not have their parathyroid glands removed or in whom surgery to remove the parathyroid glands was not effective.
Zdravilo Parareg so preučevali tudi v študiji, ki je vključevala 46 bolnikov s hiperkalciemijo, od tega 29 bolnikov s paratiroidnim karcinomom in 17 bolnikov s primarnim hiperparatiroidizmom, pri katerih ni bilo mogoče odstraniti obščitnic ali pri katerih kirurška odstranitev obščitnic ni bila učinkovita.
In dialysis patients with serious kidney disease, about 40% of the patients taking Parareg had PTH levels below 250 micrograms/l at the end of the study, compared with about 6% of those taking placebo.
Pri dializnih bolnikih s hudim obolenjem ledvic je imelo približno 40 % bolnikov, ki so jemali zdravilo Parareg, ob koncu študije ravni paratiroidnega hormona pod 250 mikrogramov na liter, v primerjavi s 6 % bolnikov, ki so prejemali placebo.
The Committee for Medicinal Products for Human Use (CHMP) decided that Parareg's benefits are greater than its risks for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy, and for the reduction of hypercalcaemia in patients with parathyroid carcinoma or primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Parareg večje od z njim povezanih tveganj pri zdravljenju sekundarnega hiperparatiroidizma pri dializnih bolnikih s končno odpovedjo ledvic na vzdrževalnem dializnem zdravljenju in za zmanjšanje hiperkalciemije pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom, pri katerih bi bila kirurška odstranitev obščitnic indicirana na osnovi ravni kalcija v krvi, vendar pa taka odstranitev zanje ni klinično ustrezna ali je kontraindicirana.
The most common side effects with Parareg in secondary hyperparathyroidism (seen in more than 1 patient in 10) are nausea (feeling sick) and vomiting.
Najpogostejša neželena učinka zdravila Parareg pri zdravljenju sekundarnega hiperparatiroidizma (opažena pri več kot 1 izmed 10 bolnikov) sta navzeja (slabost) in bruhanje.
A further three studies compared the effectiveness of Parareg and placebo in a total of 136 patients with primary hyperparathyroidism over up to a year.
nadaljnjih treh študijah so v času do enega leta primerjali učinkovitost zdravila Parareg z učinkovitostjo placeba pri skupno 136 bolnikih s primarnim hiperparatiroidizmom.
Parareg was compared with placebo (a dummy treatment).
Zdravilo Parareg so primerjali s placebom (zdravilom brez zdravilne učinkovine).
PTH levels should be assessed at least 12 hours after dosing and one to four weeks after each dose adjustment of Parareg.
Ravni paratiroidnega hormona je treba izmeriti najmanj 12 ur po zaužitju odmerka in en do štiri tedne po vsaki prilagoditvi odmerka zdravila Parareg.
In patients with parathyroid carcinoma or primary hyperparathyroidism, the side effects are similar to those seen in patients with long-standing kidney disease - the most frequent side effects are nausea and vomiting.
Pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom so neželeni učinki podobni tistim, opaženim pri bolnikih z dolgotrajnim obolenjem ledvic: najpogostejša neželena učinka sta navzeja (slabost) in bruhanje.
Cinacalcet works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands that regulate PTH secretion.
Cinakalcet deluje tako, da poveča občutljivost receptorjev za zaznavanje kalcija, ki se nahajajo na obščitnicah in uravnavajo izločanje paratiroidnega hormona.